Long Term Portfolio
Long-Term Portfolio
| Ticker | First Mention | My Entry | Last | P/L % | Market Cap |
|---|---|---|---|---|---|
| CGTX | — | — | — | — | —— |
| ALGS | — | — | — | — | —— |
| SPRO | — | — | — | — | —— |
| SLDB | — | — | — | — | —— |
EOD and Market cap from publicly available data.
Remarks
Averaged down ALGS and SLDB slightly with the dip on 31st of October.
SLDB's Q3 Earnings on 3rd of November disappointed many with the delay to the anticipated FDA meeting, however, the interim results of SGT-003 looks solid and will continue to hold into 2026.
Watchlist
| Ticker | First Mention | My Entry | Last | P/L % | Market Cap |
|---|---|---|---|---|---|
| LTRN | — | — | — | — | —— |
| IVA | — | — | — | — | —— |
EOD and Market cap from publicly available data.
Remarks
LTRN: Took profit and waiting for re-entry since the expected results weren't published in September, and an offering might be imminent.
IVA: Took profit and waiting for re-entry as the price gap between the French Exchange and NASDAQ fluctuates between 30-50% following the ATM news.
$ALGS, over 5000% potential with Best-in-class HBV & MASH candidates with strong data. The most complete independent report available for this company - Long read
by u/oquido in pennystocks
Why $SPRO Might Be One of the Safest Undervalued Biotech Plays: Backed by GSK
by u/oquido in pennystocks
$LTRN, an oncology biotech with AI potential
by u/oquido in pennystocks
Disclaimer
The information provided on this website is for informational purposes only and should not be construed as
financial, investment, legal, or professional advice. While efforts are made to ensure accuracy, no guarantee
is given regarding completeness or reliability. Visitors should conduct their own research or consult a qualified
advisor before making any decisions. External links are provided for convenience and do not imply endorsement.